These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 10683287)

  • 41. Effect of acupuncture on 6-hydroxydopamine-induced nigrostratal dopaminergic neuronal cell death in rats.
    Kim YK; Lim HH; Song YK; Lee HH; Lim S; Han SM; Kim CJ
    Neurosci Lett; 2005 Aug 12-19; 384(1-2):133-8. PubMed ID: 15893426
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats.
    Sánchez-Pernaute R; Harvey-White J; Cunningham J; Bankiewicz KS
    Mol Ther; 2001 Oct; 4(4):324-30. PubMed ID: 11592835
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Compromised circadian function in Parkinson's disease: enucleation augments disease severity in the unilateral model.
    Willis GL; Kelly AM; Kennedy GA
    Behav Brain Res; 2008 Nov; 193(1):37-47. PubMed ID: 18547659
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neuroprotective effect of genistein in 6-hydroxydopamine hemi-parkinsonian rat model.
    Baluchnejadmojarad T; Roghani M; Nadoushan MR; Bagheri M
    Phytother Res; 2009 Jan; 23(1):132-5. PubMed ID: 18693302
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of L-Dopa on circadian rhythms of 6-OHDA striatal lesioned rats: a radiotelemetric study.
    Boulamery A; Simon N; Vidal J; Bruguerolle B
    Chronobiol Int; 2010 Jan; 27(2):251-64. PubMed ID: 20370468
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differential effects of a small, unilateral, 6-hydroxydopamine-induced nigral lesion on behavior in high and low responders to novelty.
    van Oosten RV; Cools AR
    Exp Neurol; 2002 Feb; 173(2):245-55. PubMed ID: 11822888
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model.
    Chagniel L; Robitaille C; Lebel M; Cyr M
    Neurobiol Dis; 2012 Jan; 45(1):645-55. PubMed ID: 22037042
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Zhang H; Ma L; Wang F; Chen J; Zhen X
    Neuropharmacology; 2007 Jul; 53(1):125-33. PubMed ID: 17553535
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease.
    Tomiyama M; Kimura T; Maeda T; Kannari K; Matsunaga M; Baba M
    Neurosci Res; 2005 Jun; 52(2):185-94. PubMed ID: 15893579
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine.
    Meissner W; Ravenscroft P; Reese R; Harnack D; Morgenstern R; Kupsch A; Klitgaard H; Bioulac B; Gross CE; Bezard E; Boraud T
    Neurobiol Dis; 2006 Jun; 22(3):586-98. PubMed ID: 16531050
    [TBL] [Abstract][Full Text] [Related]  

  • 51. L-dopa-induced desensitization depends on 5-hydroxytryptamine imbalance in hemiparkinsonian rats.
    Kääriäinen TM; García-Horsman JA; Piltonen M; Männistö PT
    Neuroreport; 2009 Feb; 20(3):313-8. PubMed ID: 19188858
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
    Dekundy A; Pietraszek M; Schaefer D; Cenci MA; Danysz W
    Brain Res Bull; 2006 Apr; 69(3):318-26. PubMed ID: 16564428
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Unpredictable rotational responses to L-dopa in the rat model of Parkinson's disease: the role of L-dopa pharmacokinetics and striatal dopamine depletion.
    Kääriäinen TM; Käenmäki M; Forsberg MM; Oinas N; Tammimäki A; Männistö PT
    Basic Clin Pharmacol Toxicol; 2012 Feb; 110(2):162-70. PubMed ID: 21848668
    [TBL] [Abstract][Full Text] [Related]  

  • 54. D2 receptor stimulation, but not D1, restores striatal equilibrium in a rat model of Parkinsonism.
    Ballion B; Frenois F; Zold CL; Chetrit J; Murer MG; Gonon F
    Neurobiol Dis; 2009 Sep; 35(3):376-84. PubMed ID: 19501163
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
    Srinivasan J; Schmidt WJ
    Behav Brain Res; 2004 May; 151(1-2):191-9. PubMed ID: 15084435
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synergism of NBQX with dopamine agonists in the 6-OHDA rat model of Parkinson's disease.
    Löschmann PA; Kunow M; Wachtel H
    J Neural Transm Suppl; 1992; 38():55-64. PubMed ID: 1491248
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Unilateral implantation of dopamine-loaded biodegradable hydrogel in the striatum attenuates motor abnormalities in the 6-hydroxydopamine model of hemi-parkinsonism.
    Senthilkumar KS; Saravanan KS; Chandra G; Sindhu KM; Jayakrishnan A; Mohanakumar KP
    Behav Brain Res; 2007 Nov; 184(1):11-8. PubMed ID: 17765334
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.
    Eskow KL; Gupta V; Alam S; Park JY; Bishop C
    Pharmacol Biochem Behav; 2007; 87(3):306-14. PubMed ID: 17553556
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of the phosphatidyinositol-linked D1 dopamine receptor in the pharmacology of SKF83959.
    Zhen X; Goswami S; Friedman E
    Pharmacol Biochem Behav; 2005 Apr; 80(4):597-601. PubMed ID: 15820529
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
    Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
    Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.